Your session is about to expire
← Back to Search
BAY1097761 Active Dose 2 for Acute Respiratory Distress Syndrome (SEAL Trial)
SEAL Trial Summary
This trial will compare the safety and effectiveness of two different doses of a new drug, compared to a placebo, in people with a type of lung failure called ARDS.
- Acute Respiratory Distress Syndrome (ARDS)
SEAL Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.SEAL Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Does this experiment need more participants?
"Yes, this is an ongoing clinical trial that was originally posted on July 7th 2020. The listing was last updated on November 11th, 2020."
Is this study prevalent in North America?
"Currently, this trial is being hosted at 11 different hospitals including North York General Hospital in Toronto, Vancouver Island Health Authority - Royal Jubilee Hospital in Victoria, and CIUSSS de l'Est-de-l'Ile de Montreal,Installation Maisonneuv in Montreal."
What are the potential risks associated with taking BAY1097761 Active Dose 2?
"BAY1097761 Active Dose 2 is only in Phase 2 of clinical trials, so there is not much data on its efficacy. However, it did score a 2 for safety."
To what extent is this research being conducted on test subjects?
"466 patients are required to carry out this trial according to the current inclusion criteria. The sponsor, Bayer, will be running the study at North York General Hospital in Toronto, British Columbia and Vancouver Island Health Authority - Royal Jubilee Hospital in Victoria, Quebec."
Share this study with friends
Copy Link
Messenger